Abstract
Introduction

31
Alzheimer's disease (AD) is the 6 th most common cause of death in the United States; however, no effective 32 therapy exists to delay or prevent its onset or progression. 1 Neuritic plaques and neurofibrillary tangles are two 33 neuropathological hallmarks of AD, whose basic building blocks are Amyloid-β (Aβ) peptide and the tau protein, 34
respectively. Aβ is a 40 to 42 amino acid-peptide, which is generated by proteolytic cleavages of the amyloid 35 precursor protein (APP) located on chromosome 21. 2 While the precise function of APP is not known, mutations 36 in this gene are thought to lead to familial susceptibility to AD. 3 The amyloid cascade hypothesis 4 posits that 37 aggregation and extracellular deposition of the misfolded Aβ peptide (specifically, the Aβ1-42 isoform) plays a 38 causal role in several AD-related events, including neurofibrillary tangle formation, resulting in neuronal death 39 and neurodegeneration. 5 However, causality remains unproven. 6 This hypothesis has given rise to several Aβ-40 centric treatment approaches for AD, such as blocking APP cleavage using β-secretase inhibitors, which has been 41 attempted to reduce Aβ formation and deposition, but several concerns have been raised about its efficacy. 7 Tau, 42 the other hallmark of AD, is a brain-specific, axon-enriched, microtubule-associated protein 8 encoded by a gene 43 located on chromosome 17. It is phosphorylated post-translationally and has phosphorylation levels that are 44 significantly higher in brains of AD patients, suggesting that hyper-phosphorylation may lead to tau's 1 pathogenic role in AD. 9 2 At present, we lack well-founded knowledge of the set of genes whose expression affects the formation of 3 neuritic plaques and neurofibrillary tangles and the protective and pathological responses to these purportedly 4 toxic lesions: until recently, we have had limited access to gene expression data and neuropathological 5 phenotypes from post-mortem brain tissues. Biologists have only now begun gathering both gene expression 6 data and Aβ and tau measures from human brain tissues, 10 providing a new paradigm of system-level AD data 7 for information mining. As part of the Accelerating Medicines Partnership (AMP)-AD project, Sage Bionetworks 8 recently began sharing and integrating multi-dimensional human 'omic' data from more than 2,000 human 9 brains autopsied in several studies through the AMP-AD Knowledge Portal. 11 Of those studies, the Religious 10
Orders Study 12 and the Memory and Aging Project 13 (ROSMAP) are longitudinal, clinical-pathologic cohort 11 studies of aging and AD; they provide detailed neuropathology quantifications and omics data, including RNA-12
Seq, miRNA, DNA methylation, and histone modification measured in the dorsolateral prefrontal cortex of more 13 than 700 brains. The Mount Sinai Brain Bank (MSBB) study provides microarray data and partial 14 neuropathology information from 19 regions of more than 60 brains 14 and RNA-Seq data from four regions of 15 more than 200 brains. The Adult Changes in Thought (ACT) study -a longitudinal, population-based 16 prospective cohort study of brain aging and dementia-provides detailed neuropathology quantifications and 17 RNA-Seq data from four regions of around 100 autopsied brains. 15 The increasing number of studies that attempt 18 to obtain brain gene expression and neuropathology data makes meta-analysis (i.e., a statistical analysis 19 combining data from multiple studies to develop a single conclusion) an increasingly powerful approach. 20
Identifying expression markers for neuropathological phenotypes through the meta-analysis of these studies 21 involves three major challenges. First, expression datasets obtained from different AD studies often present data 22 from different brain regions that contain different cell type compositions, have different functions, and differ in 23 their relevance to AD. While we have a general understanding of how AD progresses across the brain, 16 it is not 24 of an extent that lets us assign a specific weight value to each brain region in a meta-analysis setting to identify 25 AD neuropathology mechanisms. Second, datasets from different studies involve confounding factors due to 26 differences in subject compositions or experimental procedures used to generate data (i.e., severe batch effects).
27
Finally, the brain tissues used for expression and phenotype profiling do not always match, and each study uses 28 slightly different methods to measure Aβ or tau levels. These factors lead to different sources and levels of noise 29 across studies. Given these challenges, natural questions that arise include whether we can leverage 30 discrepancies across studies or regions to filter out false positive expression markers by focusing on concordant 31 expression associations across different sources. 32
We present DECODER (discovering concordant expression markers), a probabilistic model-based framework to 33 identify robust expression markers for a phenotype (e.g., Aβ or tau levels in brain). DECODER adopts a 34 probabilistic model we designed to capture the concordance of gene expression-neuropathology associations 35 across brain regions and/or studies. Interestingly, we show that DECODER's learning algorithm to estimate the 36 model parameters needs only the expression-phenotype associations (i.e., summary statistics) computed for each 37 dataset rather than the original expression and phenotype data. Specifically, DECODER uses the Pearson's 38 correlation coefficient (PCC) between an expression level and a phenotype as a kernel that projects the original 39 expression and phenotype data into a new gene-phenotype space in which different data sources (e.g., different 40 studies, different tissues, different brain regions, etc.) are more comparable. This is an important advantage that 41
can facilitate meta-analysis, especially when we have access to only summary statistics of expression-phenotype 42 associations, not the original data. We show that concordant expression markers substantially improve statistical 43 and biological consistency compared to expression markers identified from individual studies, tissues, or brain 44 regions considered separately. 45
Our experimental results can be divided into three main categories. First, using DECODER, we identify genes 1 that are consistently associated with quantified levels of Aβ across multiple human brain regions. This 2 demonstrates the possibility of performing meta-analysis in the highly challenging setting, where datasets 3 involve study-specific confounders or brain region-specific biological processes. Second, by applying DECODER 4 to expression-tau associations in AD and expression-patient survival associations in cancer, we show that 5 DECODER is a powerful general meta-analysis framework widely applicable to various phenotypes or diseases. 6
Third, we experimentally validate the identified expression markers for Aβ in an animal model of Aβ 7 proteotoxicity in vivo. We show that knockdowns of a mitochondrial Complex I gene very highly ranked by 8 DECODER and 13 additional Complex I genes attenuate disease in a nematode genetically modified to express 9 human A1-42, which causes an age-related paralysis phenotype. Our experimental results advance scientific 10 knowledge of C. elegans biology by revealing functions of previously uncharacterized C. elegans genes and a 11 potential mechanism for how Aβ toxicity is regulated in this nematode. More importantly, our results reveal 12
Complex I to be a promising therapeutic target for AD and offer hope for the treatment of this disease. 13
The development of DECODER and in vivo confirmatory experimentation of DECODER's findings in C. elegans 14 address fundamental limitations of the standard computational approach to biomarker discovery, which focuses 15 on genes whose expression levels are statistically associated with a phenotype of interest 3-6 (e.g., 16 neuropathological phenotypes of neuritic plaques or neurofibrillary tangles). Unfortunately, false positive 17 findings are very common in this approach, as evidenced by the low success rates (less than 1%) of replication 18 in independent datasets and translation to clinical practice. In recent years, significant research has focused on identifying genes that influence the risk of developing, age 26 of onset, and progression of AD. Mutations in genes APP, PSEN1, and PSEN2 are known to cause familial early-27 onset AD. 17 In addition, several bona fide genes for late-onset sporadic AD have been identified by genome-28 wide association studies (GWAS), including APOE, CLU, ABCA7, SORL1, PICALM, PLD3, and ADAM10. 18 
29
However, those genetic modifiers account for only a small fraction of AD risk 19, 20 and provide no clear picture 30 of AD neuropathology mechanisms. With the growing availability of expression and neuropathological 31 phenotype data, DECODER will facilitate the pace of discovery in molecular mechanisms of AD pathogenesis. 32
33
Results
34
This work seeks to identify robust expression markers for disease phenotypes, specifically expression markers 35 for the Aβ neuropathological phenotype, which could be used as therapeutic targets for individuals with AD.
36
We leverage concordance of expression associations with neuropathological phenotypes to filter out noise and 37 extract information likely to be enriched for true signals from big high-throughput brain tissue data. We 38 hypothesized that while varied brain regions are affected by AD throughout the progression of the disease and 39 each of these regions is affected with different severities across individuals in the same stage of AD, the basic 40 molecular mechanisms driving the development of and response to neuropathology might be common across 41
regions. Thus, we believe that genes whose associations with neuropathology are concordant in multiple brain 42 regions and studies are more likely to be true molecular markers, and we can use association concordance to 43 reduce the dimensionality of gene expression data into a smaller set of highly informative genes. 44
Our experiments use data from the ACT study and the AMP-AD RNA-Seq studies, which quantify 1 neuropathology findings. 11 Thus, we draw data from a total of nine brain regions and 1,746 post-mortem brain 2 tissue samples described in three different studies -ROSMAP, 12 
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ROSMAP-DPFCx 4. We hypothesize that the development of neuropathology is driven by similar molecular mechanisms in different 7 brain regions, which is also supported by the results displayed in Table 2 and Figure 2 . Therefore, focusing on 8 the concordant molecular markers across different regions could lead to the discovery of reliable genes driving 9
Aβ neuropathology. We propose a generative probabilistic model of neuropathology based on gene expression 10 levels, and then we learn model parameters, each corresponding to a gene expression level's true association 11 with the neuropathology feature, concordant across brain regions (Methods). Starting with this probabilistic 12 model, we learn the true expression-neuropathology associations in three different ways: (1) we equally weigh 13 the observed associations in each brain region to maximize the data log-likelihood, (2) we combine brain regions 14 with different weights so that this combination captures as much data variation as possible, and (3) we non-15 linearly combine individual region scores so that we can accurately reconstruct them from this combination 16 (Methods). Each approach generates a single quantitative score for each gene representing its neuropathology 17 marker potential, and we use these potentials to rank the genes. We refer to the new gene scores identified by 18 these three approaches as the "equal weights score (EWS)", "maximum variance score (MVS)", and "best 19 reconstruction score (BRS)", respectively. 20 EWS and MVS both linearly combine regional associations (Methods). However, EWS equally weights the 21 regions, while MVS learns the weights associated with different regions from the input data. We observed that, 22 when applied to gene expression-Aβ associations, MVS highly weights regions previously known to be relevant 23 to AD (Figure 3 ). The regions MSBB-BM36 and MSBB-BM22, which coincide with the medial temporal lobe (the 24 brain part where AD-related cellular and structural alterations begin and have a more severe effect 22 ), are the 25 top two regions with the highest weights. White matter is suggested to be less vulnerable to AD than gray 26 matter, 23 and, interestingly, the white matter region ACT-FWM is assigned the lowest weight. Similarly, the 27 dorsolateral prefrontal cortex region is affected in later stages of AD progression, 16 and ROSMAP-DPFCx was 28 also assigned a relatively lower weight. We performed a cross-validation (CV) experiment to test whether the gene scores identified based on 13 concordance across multiple regions (i.e., EWS, MVS, or BRS) are statistically more robust and informative than 14 scores from individual region-based approaches (i.e., the association of gene expression with Aβ levels in each 15 individual region). We also compared our concordance-based approaches to Fisher's method, which is widely 16 used to derive a single -value from multiple associations with different significance levels (i.e., -values). 17
Fisher's method assigns to each gene a score that is proportional to the mean negative logarithm of the individual 18 -values. In our experiments, we use Fisher's method to combine nine -values obtained by performing 19
Pearson's correlation test for each brain region. 20
In our CV experiment to test statistical consistency, for each of the nine regions used as a test fold, we used the 21 other eight regions for training. For each test fold, we computed how well the gene scores from each of the eight 22 individual regions, Fisher's method, EWS, MVS, and BRS estimated test fold scores. Note that DECODER and 23
Fisher's method computed scores based on the eight training regions. We used a Spearman rank correlation 24 between the actual vs. estimated gene scores to measure each method's performance. We observed that our 25 concordance-based approaches outperformed all alternatives in statistical consistency averaged across the nine 26 regions used for testing ( Figure 4 ). Thus, gene rankings are statistically more robust (i.e. likely to be replicated 27 in an independent, unobserved dataset) when obtained based on the concordance of expression-neuropathology 28 associations across regions compared to when determined based on an individual region or Fisher's method.
29
While the three concordance-based approaches performed similarly in terms of statistical consistency, we 30 observed a very slight increase in performance with an increase in complexity of the approach we used to learn 31 the scores (i.e., BRS performed slightly better than MVS, which in turn performed slightly better than EWS) 32 (Methods). Fisher's method works with -values rather than observed associations. Therefore, to compute Fisher's method 5 consistency in a way comparable to other methods, we averaged consistency results over two different Fisher's 6 method choices: one choice combines -values from a one-sided correlation test with an alternative hypothesis 7 of negative correlation, and the other with an alternative hypothesis of positive correlation. Supplementary 8 Figure 4 shows Fisher's method bars separately from those two alternatives. 9
Fisher's method achieves a relatively lower statistical consistency, likely because it generally puts a higher 10 weight on highly-sampled regions since smaller association -values are often obtained from those. However, 11
highly sampled regions may not be the most relevant to AD. In our experimental setting of nine regions, 12 ROSMAP-DPFCx includes the highest number of samples (Table 1) . However, the dorsolateral prefrontal cortex 13 is usually affected later as AD progresses 16 and is therefore not as relevant to AD as several other regions with a 14 smaller sample size in our data. 15
16
Result 4. CEMs are highly enriched for genes known to be relevant to AD. 17
In addition to statistical relevance, we also assessed the biological relevance of the top-scoring genes from the 18 EWS, MVS, and BRS that we propose as part of our DECODER framework. To do this, we checked whether the 19
CEMs identified by concordance-based approaches are more likely to be relevant to AD compared to the top 20 genes identified by individual region-based approaches and Fisher's method. The biological relevance metric 21
we use is the number of genes overlapping with the 'KEGG_ALZHEIMERS_DISEASE' pathway (AD pathway) 22 from the C2 collection (curated gene sets from online pathway databases) of the Molecular Signatures Database 23 (MSigDB). 24 This pathway contains 169 genes in total, 144 of which exist in all gene expression datasets from the 24 nine brain regions we use in our experiments (Supplementary Table 1) . 25
For each of the nine individual region-based approaches, Fisher's method, EWS, MVS, and BRS, we selected the 26 top N genes, where genes were sorted based on their score assigned by the method. Then, for each = {1, . . . , }, 27
we analyzed the number of genes that overlap with the 144 AD pathway genes. We repeated the analysis for the 28 "negative tail" and "positive tail" from each method; these terms refer to genes to which the method assigns 1 highly negative scores and highly positive scores, respectively. Figure 5 presents the results averaged over the 2 two tails for each method; the curves corresponding to EWS, MVS, and BRS (purple, green, and black solid 3 curves, respectively) are above all other curves. This means that concordance-based approaches identify more 4 true positives earlier than alternative approaches (i.e., individual region-based approaches represented by nine 5 non-solid curves and Fisher's method represented by the yellow solid curve). As mentioned earlier, one choice 6 of Fisher's method combines -values from a one-sided correlation test with an alternative hypothesis of 7 negative correlation, and the other with an alternative hypothesis of positive correlation. The negative and 8 positive tails for Fisher's method refer to the top genes from these alternatives, respectively. To further investigate the biological relevance of CEMs, we examined the functional enrichment of 50 CEMs 1 from the negative and positive tails of EWS, MVS, and BRS, where those tails correspond to genes that are 2 assigned highly negative and highly positive scores, respectively. We considered 1,077 Reactome, BioCarta, and 3 KEGG GeneSets (canonical pathways) from the C2 collection (curated gene sets from online pathway databases) 4 of the MSigDB. 24 We computed the significance of the overlap between each GeneSet and the 50 CEMs measured 5 by Fisher's exact test (FET) p -value and then applied false discovery rate (FDR) correction for multiple 6 hypotheses testing for the 1,077 pathways. 7
The 50 CEMs from the Aβ negative tail of the EWS, MVS, and BRS were all significantly enriched for seven 8 pathways (FET ≤ 0.05), as shown in Table 3 . These include known pathways for neurodegenerative diseases, 9 including Parkinson's disease and Huntington's disease, in addition to AD. Other pathways in the table involved 10 the electron transport chain or oxidative phosphorylation, implicated in a variety of neurodegenerative 11 processes. [25] [26] [27] Interestingly, the positive tail did not exhibit significant pathway enrichment for any of the three 12 approaches. Since EWS generally achieved a more significant pathway enrichment than MVS or BRS (Table 3) , 13
we decided to pay particular attention to CEMs on the negative tail of EWS for our further experiments with 14
CEMs. 15 To test the applicability of the DECODER approach to other phenotypes or diseases, we also applied it to: (1) 24 gene expression-tau associations from the nine brain regions (AD studies), and (2) gene expression-survival 25 associations from 33 cancer types (The Cancer Genome Atlas (TCGA) study). Through these experiments, we 26 aimed to obtain: (1) the gene markers whose expression levels are predictive of tau pathology across different 27 brain regions, and (2) cancer patient survival across different cancers. 28 Figure 6 shows a heatmap of gene expression-tau neuropathology associations and the statistical and biological 29 consistency results from applying DECODER and the alternative methods to these associations. Each row in the 30 heatmap ( Figure 6A ) represents one of the nine brain regions in Table 1 , and each column represents one of the 31 14,912 protein-coding genes whose expression was measured in all nine regions. As was the case in the heatmap 1 for expression-A associations (Figure 2) , regions from the same study tend to group together in the heatmap 2 for tau associations. Still, MSBB-BM44, a frontal cortex region from the MSBB study, connects to another frontal 3 cortex region from a different study, ROSMAP-DPFCx, before it connects to other cortical regions from the MSBB 4 study. Concordance-based approaches estimated unobserved test region scores more accurately than individual 5 region-based approaches and almost as accurately as Fisher's method ( Figure 6B ). Moreover, of 14,912 total 6 genes, 144 genes in the 'KEGG_ALZHEIMERS_DISEASE' pathway (Supplementary Table 1 ) exhibited a large 7 overlap with negative tail tau CEMs earlier than the highly ranked genes by individual region-based approaches 8 or Fisher's method ( Figure 6C ). between KEGG AD pathway genes and the highly ranked genes by each approach. 6 Figure 7 shows a heatmap of TCGA gene expression-survival associations and the statistical and biological 1 consistency results from applying DECODER and the alternative methods to these associations. Here, our 2 hypothesis is that focusing on gene expression-survival associations concordant across different cancers may let 3 us identify molecular markers generally important in cancer prognosis and may highlight prognosis-related 4 molecular mechanisms in cancer. 5
16
Each row in the heatmap ( Figure 7A ) represents one of 33 cancer types, and each column represents one of the 6 15,097 genes included in the TCGA RNA-Seq data from all cancer types. Cancer is a heterogeneous disease, and 7 survival is a phenotype that could be affected by a diverse set of factors. So, not surprisingly, we did not observe 8 a visible clustering structure in the dendrogram of gene expression-phenotype associations. Still, concordance-9 based approaches, specifically MVS and BRS, estimated unobserved gene scores from the test cancer type ( Figure  10 7B) more accurately than alternative approaches. Furthermore, of 15,097 total genes, 118 genes in the 11 'KEGG_CELL_CYCLE' pathway exhibited a large overlap with negative tail survival CEMs earlier than the 12 highly ranked genes by individual region-based approaches or Fisher's method ( Figure 7C ). This is not 13 surprising given that the dysregulation of cell cycle-regulated genes is common in many cancers and has been 14 associated with poor prognosis. 
animal model of A proteotoxicity. Over the last two decades, C. elegans has been a particularly useful model 3 system for studying genetic pathways that influence proteotoxicity since transgenic strains are easily constructed 4 and maintained, and genes are efficiently knocked down by RNAi. 31, 32 We conducted experiments with a 5 transgenic worm line displaying an age-associated aggregation of human A1-42 peptide in their body wall 6 muscle cells. 33 The proteotoxic stress induced by the human transgene results in a rapid onset of age-associated 7 paralysis. 8
To identify CEMs that function as modifiers of A toxicity, we first identified nematode orthologs for the 20 9
CEMs on the negative tail from EWS (Table 4 ) using a stringent (BLAST -value ≤ 10 −30 ) reciprocal best hits 10 (RBH) approach (Methods). This approach identified seven unique human genes with at least one RBH, 11 highlighted in blue in Table 4 . Interestingly, of those seven genes, only NDUFA9, a component of the 12 mitochondrial electron transport chain (mETC) Complex I, was contained in any of the seven canonical 13 pathways for which the top CEMs were enriched (Table 3) , and all of these seven canonical pathways contained 14 NDUFA9. For these reasons, we focused first on the worm ortholog of NDUFA9, encoded by the gene Y53G8AL.2. 15 
To We note that identifying the NDUFA9 gene would not be possible by examining the top genes from a single 19 region or Fisher's method, as shown in Table 5 . Concordance-based scores led to a high ranking of the NDUFA9 20 gene and made it possible to computationally identify its significance, which led to its biological validation in C. 21 elegans. 22 23 Given that NDUFA9 -a gene with an important role in ATP synthesis and mitochondrial function -2 significantly suppressed paralysis, we also performed RNAi knockdown experiments to test the C. elegans 3 homolog of ATAD1, the other CEM in Table 4 that is relevant to the ATP metabolism. Prior research showed 4 that ATAD1 maintained mitochondrial function. 37 ATAD1 is a member of the ATPase family which is a class of 5 enzymes that catalyze the decomposition of ATP into ADP. ATPase plays a critical role in regulating the surface 6 expression of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors that are ionotropic 7 transmembrane receptors for glutamate and mediate fast synaptic transmission in the central nervous system. 8 AMPA receptor-related changes are a core feature of age-related cognitive decline. 38 Thus, ATAD1 plays an 9 important role in regulating synaptic plasticity as well as learning and memory. We observed a significant 10 suppression of paralysis in the C. elegans Aβ strain when it was treated with ATAD1 homolog K04D7.2 (mspn-1) 11
( Figure 8C ). 12
13
Result 8. Knockdown of NDUFA9's nematode homolog strongly decreases whole animal oxygen consumption. 14 Y53G8AL.2, the nematode homolog of the human NDUFA9 gene (Table 4) , showed robust suppression of 15 paralysis in our RNAi knockdown experiments in C. elegans ( Figure 8A ). Consistent with its homology to human 16 NDUFA9 -an important component of the mETC -Y53G8AL.2 has been shown to impact oxidative 17 phosphorylation in isolated mitochondria. 39 However, no studies have directly investigated the impact of 18 Y53G8AL.2 on organismal respiration. Because Y53G8AL.2 has not been extensively studied in C. elegans, we 19 sought to confirm that the gene encodes a functional component of the mETC, as predicted by its homology to 20 NDUFA9. Consistent with such a role, we observed that RNAi knockdown of Y53G8AL.2 strongly decreases 21 whole animal oxygen consumption (Methods) (Figure 9 ). Thus, we concluded that reduced expression of the 22 NDUFA9 homolog Y53G8AL.2 robustly attenuates Aβ toxicity and impairs the function of Complex I of the 23 mETC. 24
25
Figure 9. Knockdown of NDUFA9 homolog Y53G8AL.2 greatly reduces whole animal oxygen consumption. O2 26 consumption is normalized to the O2 consumption rate of one animal on control RNAi (EV). *** p-value less than 1e-3. 27
Result 9. In vivo validation of 13 additional Complex I genes identifies mitochondrial Complex I as a potential AD target. 1
Thus far, we have established that: (1) CEMs were significantly enriched for functional categories relevant to 2 mitochondrial respiration, ATP synthesis, and mETC, all including NDUFA9 (Table 3) , and (2) knockdown of 3 the nematode homolog of NDUFA9, a subunit of mETC Complex I, strongly suppressed paralysis ( Figure 8A ) 4 and significantly decreased whole animal oxygen consumption in C. elegans ( Figure 9 ). We therefore 5 hypothesized that Complex I may act as a key regulator of Aβ toxicity. We first sought to confirm that the 6
Complex I genes exhibit a cluster structure in the 2-dimensional space that explains the highest amount of 7 variance in the gene expression-Aβ associations from nine regions (i.e., the space of the first two principal 8 components). Supplementary Figure 2 shows that most of the Complex I genes, represented by blue dots, are 9 projected very closely to each other in the first two principal components space of expression-Aβ associations.
10
This observation suggests that Complex I genes have similar Aβ association levels, and that other Complex I 11 genes might also function, like Y53G8AL.2, as modifiers of Aβ-induced toxicity. To test this hypothesis, we 12 individually knocked down 13 additional C. elegans genes that encode homologs of human Complex I proteins 13 (Table 6) 
Result 10. A multi-omic module subnetwork involving Complex I highlights mechanisms relevant to AD. 1
Given our conclusion that mETC Complex I is a critical mediator of Aβ proteostasis, another important question 2 concerns how Complex I is regulated in this process. Molecular processes are orchestrated by a complex 3 interplay between different genetic and epigenetic regulatory elements. The ROSMAP study 12, 13 provides DNA 4 methylation and microRNA (miRNA) measurements from the same individuals in addition to mRNA 5 expression data for 542 individuals used in our concordance-based gene ranking framework (Table 1) . These 6 additional data types let us investigate how Complex I is regulated in a multi-omic setting. 7
We applied the MGL 40 algorithm to a data matrix of 35,354 variables from three types of molecular data -mRNA, 8 DNA methylation, and miRNA -in the ROSMAP study and learned a multi-omic module network that might 9
shed light on the regulatory mechanisms in AD (Methods). DNA methylation and miRNAs are important 10 epigenetic mechanisms posited to play an important role in AD, especially because environmental factors affect 11 aging through epigenetic modifications in an individual. 41 12 Figure 11 shows the subnetwork of the learned module network that represents the modular dependency 13 structure for the Complex I modules. This subnetwork includes ten modules that are: (1) connected to at least 14 three of the eight modules that are significantly enriched (FET ≤ 0.05) for Complex I genes, and (2) either 15 significantly enriched for a functional pathway or contain either a DNA methylation site or a miRNA. Next to 16 each module in Figure 11 , we list the top pathway for which this module is significantly enriched. Eight of the ten modules in the Figure 11 subnetwork contain only genes (mRNAs), and each of these modules 1 is significantly enriched for pathways that are relevant to AD. The other two modules -modules 12 and 489 -2 contain non-mRNA variables (i.e., methylation or miRNA), and they are both connected to module 21, which is 3 the hub in the subnetwork (i.e., connected to many other modules) and significantly enriched for Complex I 4 genes. It was suggested earlier that reduction in mitochondrial function alters the expression of genes that 5 mediate DNA methylation. 42 It was also suggested that increased Aβ levels promote the production of reactive 6 oxygen species that cause DNA oxidation; and DNA methylation events modify susceptibility to DNA oxidation, 7 resulting in the acceleration of neurodegenerative events. 43 Therefore, it is not surprising that module 21 has a 8 dependence on module 489, which contains 150 methylation sites. Supplementary Table 2 lists the 80 unique  9 genes to which these 150 methylation sites are mapped. The other module connected to module 21 and 10 containing non-mRNA variables, module 12, contains miRNA hsa-miR-633, which was shown to be down-11 regulated in AD. 44 Given that NDUFA9 and most other Complex I genes were highly ranked on the negative tail 12 of concordance-based gene scores for Aβ (i.e., down-regulated in AD) (Supplementary Table 4) , an up-regulation 13 between module 21 and module 12 is not surprising. This up-regulation is represented by the blue edge between 14 modules 21 and 12 in Figure 11 . We observed that the 95 genes in module 12 significantly overlap ( < 0.05) 15
with the 1,231 target genes of hsa-miR-633 that are predicted by miRDB, 45 In this work, we introduced DECODER, which probabilistically models observed data to capture concordant 40 associations between gene expression and neuropathology across different brain regions. We learned model 41 parameters using three different approaches -equal weights score (EWS), maximum variance score (MVS), and 42 best reconstruction score (BRS). Each approach assigned a score to each gene, enabling us to rank genes based 43 on the level of agreement of brain regions on the association between gene expression and neuropathology. We 44 demonstrated that each concordance-based approach reduces the rate of false positive associations and, thus, 1 increases the chance that the identified genes are relevant to AD. This process led us to a short list of potential 2 AD neuropathology biomarker genes, which we call concordant expression markers (CEMs), that are highly 3 ranked by our concordance-based approaches. CEMs were enriched for several pathways relevant to the 4 mitochondrial electron transport chain (mETC). The gene NDUFA9, involved in mETC, is a highly ranked CEM.
5
This gene was identified to be differentially down-regulated between cognitively normal controls and AD 6 individuals in four brain regions and significantly correlated with Aβ in mouse models. 49 We tested NDUFA9 7 and 13 other Complex I genes in C. elegans Aβ proteotoxicity models and showed that knockdown of each 8
Complex I gene significantly suppresses Aβ toxicity. 9
Our findings suggest that mild Complex I inhibition could be a new paradigm for developing future AD 10 therapeutics. Although it may seem paradoxical that mild inhibition of Complex I is protective, given that 11
Complex I expression is lower in the brains of AD patients compared to healthy controls, a reduction in gene 12 expression could simply reflect a protective response to pathological changes occurring during the disease. Prior 13 work has indicated that mild inhibition of Complex I with the small molecule CP2 reduced Aβ and tau levels in 14 mouse models of familial AD. 50 Capsaicin is a natural product that can inhibit Complex I, and a capsaicin-rich 15 diet was associated with lower total serum Aβ levels in the elderly. 51 Furthermore, capsaicin reduced AD-16 associated tau changes in the hippocampus of type 2 diabetes rats. 52 These earlier studies' findings, combined 17 with our novel results from the brain region concordance-based approaches, suggest that Complex I is indeed a 18 promising potential pharmacological avenue toward treating AD. 19
The C. elegans gene K04G7.4 (nuo-4) -ortholog of the human Complex I gene NDUFA10 -was the strongest 20 suppressor of Aβ toxicity, a gene shown to be significantly enriched in serotonergic neurons compared to whole-21 animal expression. 53 Given that our C. elegans model expresses human Aβ1-42 peptide solely in body wall muscle 22 cells, this suggests the possibility that cell non-autonomous, neuron-to-muscle signaling mediates the regulation 23 of Aβ toxicity following Complex I inhibition in C. elegans. Prior studies using C. elegans have shown that 24 neuronal signaling and endocrine pathways are integrated into the physiology of other tissues in the organism, 25 including the regulation of heat shock response modulation of protein homeostasis in post-synaptic muscle 26 cells. [54] [55] [56] Interestingly, neuronal RNAi of mETC genes is sufficient to extend lifespan in worms and can induce 27 changes in gene expression in the intestine including activation of the mitochondrial unfolded protein 28 response. 57 This mitochondrial stress response has been proposed to increase lifespan 57 and recently implicated 29 in suppression of Aβ toxicity in worms 58 . However, other studies have shown that the lifespan extension is 30 independent of the mitochondrial unfolded protein response. 59-62 It will be of interest to determine whether 31 activation of the mitochondrial unfolded protein response plays a role in suppression of Aβ toxicity following 32
Complex I inhibition, and whether these effects of Complex I inhibition are cell-autonomous or cell non-33 autonomous. 34
One limitation of our computational experiments to test DECODER's performance on identifying 35 neuropathology marker genes is that the neuropathological phenotype quantifications we used for some of the 36 nine brain regions had not been obtained exactly from that phenotype or region. For the MSBB RNA-Seq samples, 37 no tau, tangle, or Aβ quantifications were provided. Therefore, we used Braak stages as a proxy for tau levels 38 since Braak staging is based on the regional distribution pattern of neurofibrillary tangle density across the 39 brain, 63 and we used the neuritic plaque density mean across five cortical regions as a proxy for Aβ. Thus, the 40 samples from the four different MSBB regions were assigned the same values for Aβ and the same values for 41 tau. Moreover, histelide 64 Aβ quantification was provided for only two of the four ACT regions -ACT-TCx and 42 ACT-PCx. Therefore, we used ACT-PCx Aβ levels for ACT-FWM and ACT-TCx Aβ levels for ACT-HIP based 43 on regional proximity. We surmise that regions from the same study tend to group together in the heatmaps in 44 Figure 2 and Figure 6 partly because of these study-specific arrangements we made due to limited data 1 availability. 2 DECODER is a general framework applicable to any omic data type (e.g., proteomic, metabolomic) besides 3 transcriptomic data as long as it is possible to get association statistics, such as correlation coefficients, from the 4 data. Therefore, we expect a wider availability of AD multi-omic data to let us apply DECODER to identify 5 concordant neuropathology markers from other molecular data types as well. 6
Another important direction for future work is to develop a systematic approach to iterate between a 7 computational algorithm phase and a biological validation phase. At each iteration, the computational algorithm 8 can be improved using causal markers identified by the experiments in the previous biological validation phase, 9
which could lead to a new set of genes to test in C. elegans and/or other model organisms in the next biological 10 validation phase. Biological validation experiments let us identify causal relationships; however, it can be highly 11 challenging to conduct biological experiments on a large number of genes due to limited lab resources. On the 12 other hand, computational resources are relatively cheaper; however, reliably identifying causal relationships is 13 known to be an NP-hard problem. 65 The described iterative algorithm takes advantage of both sides by 14 improving the set of computationally identified genes utilizing experimentally learned causal relations. 15
We conjecture that DECODER will become even more powerful in the near future as the number of AD studies 16 providing brain gene expression and neuropathology data continues to increase. Many of these studies also 17 provide multi-omic data, which will let us utilize a higher sample size for learning regulatory multi-omic module 18 networks for identified biomarker genes. 19
20
Methods 21
Gene expression and neuropathology datasets 22
We used data from the ROSMAP, 12,13 ACT, 15,21 and MSBB studies. Around half of the people in each cohort had 23 been diagnosed with dementia by the time of death. MSBB neuropathology data was made available by the 24 AMP-AD Knowledge Portal of Sage Bionetworks through https://www.synapse.org/ with Synapse ID 25 syn6101474. We accessed neuropathology data from the ROSMAP and ACT studies through data use 26 agreements. ACT neuropathology data includes four types of Aβ and tau quantifications: (1) 27 immunohistochemistry (IHC) measured on fresh-frozen brain tissue, (2) IHC measured on formalin-fixed, 28 paraffin-embedded (FFPE) brain tissue, (3) histelide 64 quantification from FFPE slides, and (4) Luminex. We 29 chose histelide for Aβ and IHC FFPE for tau since these two led to the strongest average association with gene 30 expression levels. 31 ROSMAP RNA-Seq data and MSBB RNA-Seq data were made available by Sage Bionetworks on the AMP-AD 32
Knowledge Portal 11 with Synapse IDs syn3505732 and syn7391833, respectively. The ACT RNA-Seq data 15 was 33 collected by the Allen Institute for Brain Science, Kaiser Permanente Washington Health Research Institute 34 (KPWHRI), and the University of Washington (UW), and it was made available on http://aging.brain-map.org.
35
We used normalized and log-transformed RNA-Seq read counts for all datasets. 36 ACT RNA-Seq data is part of the larger ACT project -a collaboration between KPWHRI and UW -that 37 collected clinical and genetic data from thousands of individuals. The approximately 100 ACT individuals from 38 whom we have RNA-Seq measurements were specifically selected for a traumatic brain injury (TBI) study; half 39 of the selected individuals sustained a TBI with loss of consciousness during their lifetime. As a result, the RNA-40
Seq cohort does not necessarily reflect the demographics of the entire set of thousands of ACT individuals. 41 Therefore, the ACT study assigned each RNA-Seq sample a weight based on the demographic information of 42 each sample in the TBI study. Details of this weighting scheme and the weights themselves are provided on 1 http://aging.brain-map.org. As recommended by the ACT study, we took the weights into account when 2 computing gene expression-neuropathology associations for the ACT data so that the samples reflect the original 3 ACT cohort demographics. 4
5
Probabilistic modeling of the relation between neuropathology and gene expression levels 6
Let us assume that for each of brain regions, we observe a data matrix ∈ ℝ × that contains the gene 7 expression measurements on genes and for samples (i.e., individuals), and we also observe a 8 neuropathology feature for the same samples, represented by a column vector ∈ ℝ . Let us also assume 9 that and are standardized so that each column in each matrix has a mean of 0 and variance of 1. 10
We model the data observed for the brain region r using the following generative model, where ( , ) 11
represents the joint probability distribution of the neuropathology feature and the expression level of gene , 12 both measured in that region: 13
Assuming a Gaussian distribution for the conditional ( | ) and a uniform prior distribution over : 15
where is a gene index and is a region index, and is a parameter that represents the true association we 17 want to learn between the expression level of gene and the neuropathology feature. 18
Using the probability density formulation of Gaussian distribution and assuming independent samples: 19
represents the squared Euclidean norm of ( − ). 21
Assuming the brain regions are also independent of each other: 22
Eq. (4)
23 Therefore: 24
Eq. (5)
25
To learn the true association between the expression level of gene and the neuropathology feature based 26 on this probabilistic model, we maximize the joint log-likelihood, which corresponds to the following 27 optimization problem: 28
.
Eq. (6)
29
Note that we assume a fixed 2 for simplicity. When we take the derivative of this objective function with respect 1 to and set it to zero to get the minimizing it, we get: 2 correspond to the scores obtained by our equal weights score (EWS) approach. 10
As Eq. (9) shows, EWS computes the true association for each gene as the mean of the regional associations for 11 that gene. Thus, it equally weighs each region while computing the true gene-neuropathology associations, 12
where each weight value is equal to 1⁄ . Figure 12A represents EWS, where region weights are assumed to be 13 equal; hence, the final gene scores are computed as the average across input region associations. 14 However, different regions are likely to have a different importance in AD; rather than assuming equal weights, 15
we may want to learn the weights for each region while computing the true underlying association 16 for each gene. Therefore, the maximum variance score (MVS) approach assumes that the true neuropathology 17 association for each gene is a weighted mean of the individual region-based associations for that gene: 18
where represents a row of ∈ ℝ × , the matrix representing the individual region-based PCCs between genes 20 and neuropathology in each region, and ∈ ℝ is a column vector representing region weights such that 21 ∑ = 1 ( Figure 12B ). represents as much information about the regional neuropathology associations as possible (i.e., we maximize 7 the variance). That is how MVS learns the weight values. 8
Without loss of generalization, we assume that the true association vector has a mean of 0 across all genes 9 ( ∑ = 0 ). Thus, maximizing the variance of the data through corresponds to the following 10 optimization problem: 11
Eq. (11)
12
Since ∑ = 1, = 1, the preceding optimization problem is equivalent to 13 max .
Eq. (12)
14
Since is a positive semi-definite matrix, the vector that maximizes the quantity (also known as the 15 The MVS objective while learning (i.e., the weights of the individual regions in Eq. (10)) is to capture the 1 maximum variance in the input associations by projecting them onto the direction of . Another objective 2 would be to reconstruct input associations from (by multiplying back by ) as accurately as 3 possible (i.e., with a minimal error between the input associations and the reconstructed associations). Then the 4 objective becomes: 5
Eq. (13) This objective has been shown to lead to the same vector as that learned by MVS above. 66 To learn a distinct 6 using our best reconstruction score (BRS) approach, we add an additional layer of weights and a nonlinear 7 activation function (. ) on the input supplied to the hidden layers ( Figure 13 ). Nonlinear activation is needed 8 because a network with several layers of linear units can always be collapsed into a single-layer linear network 9 by multiplying the weights in the proper way, which still would be equivalent to the MVS architecture ( Figure  10 12B). 66 For MVS, a linear activation function is applied to the input values (i.e., identity function ( ) = ). 11
Both EWS and MVS learn a linear embedding of the input data from the individual regions to a single-12 dimensional vector. Non-linear embedding is useful since it may enable us to capture more complex 13 relationships between input variables (i.e., brain regions) and the learned low-dimensional space. 14 After incorporating an additional layer of weights and nonlinear activations, the final BRS objective we use is: 15
Eq. (14) where ̂= 1 ( ( 2 ( ( 2 ( 1 ) represents the data reconstructed by the BRS (i.e., the reconstructed PCCs).
16
As demonstrated in Figure 13 , we use hyperbolic tangent function ℎ (. ) as the activation function (.), and 17 we use (= 9) hidden units in the intermediate hidden layer. Thus, 1 ∈ ℝ × is a 9 × 9 matrix, and 2 ∈ ℝ 18 is a 9-vector similar to in MVS. We use a linear activation function in the output layer and the mean-squared 19 error (MSE) to measure reconstruction quality (Eq. (14)) since gene expression-neuropathology associations ( ) 20 are continuous-valued between -1 and 1. The three dots in each of the encoder and decoder networks in Figure  21 13 imply full-connectivity in the intermediate layer.
22
Unlike EWS or MVS, the cost function of BRS is not convex. A common approach to learning 1 and 2 is to 23 start with some random weight values and iteratively forward/backward propagate through the network 24 ( Figure 13 ) to update weight values. 67 In each iteration, the reconstruction error is computed first by forward 25 propagation; gradients that reduce the error are then computed through back-propagation; and weights are 26 updated according to those gradients. Since the cost function of BRS is non-convex, the resulting weights may 27 depend on the weight values at initialization. Therefore, we performed 100 BRS runs initialized with different 28 random weights and averaged the results across these runs. To examine cancer survival associations, we used clinical data and RNA-Seq data provided by the Broad 9 Institute (http://gdac.broadinstitute.org/). We used the "SurvCorr" 68 R package available on CRAN to estimate 10 a correlation between a right-censored survival time and a gene expression level. Table 7 lists the expansions for  11 cancer type abbreviations we used in our experiments with TCGA data: 12 
Identification of C. elegans orthologs 3
To enable biological testing of the human genes identified using our computational analysis, we obtained the 4 RBHs between human and C. elegans. To do so, we first identified all unique protein sequences for each potential 5 marker gene using the "biomaRt" 69 R package available on CRAN. Then, we used the latest version of the NCBI 6 BLAST tool 70 , which we downloaded from ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST, version 7 2.6.0 as of 8/15/17, to identify the C. elegans orthologs for each complete human protein query sequence. We 8 downloaded the C. elegans protein sequences from http://www.wormbase.org/species/c_elegans. We took into 9 account only the protein pairs mapped from human to C. elegans with a BLAST -value smaller than 10 −30 . For 10 each C. elegans isoform, we identified the corresponding human genes, again using the NCBI BLAST tool, and 11 used only the orthologs that achieved a BLAST -value smaller than 10 −30 . This process resulted in high-12
confidence RBHs for us to test in C. elegans. 13 14
C. elegans cultivation and RNAi treatment 15
Experimental worm populations of GMC101 animals were obtained from the Caenorhabditis Genetics Center 16 (CGC) and cultivated on NGM plates with OP50 at 15C. 33, 71 Care was taken to ensure that the animals were never 17 starved and the plates remained free of contamination. 18
The gene-specific RNAi clones were obtained from the commercial Ahringer or Vidal C. elegans RNAi-feeding 1 libraries (BioScience, Nottingham, UK). Each bacterial clone was struck-out onto LB plates containing 2 carbenicillin (50 ug/ml) and tetracycline (10 ug/ml). Single colonies were then seeded into 5 ml LB + carbenicillin 3 (50 ug/ml) and tetracycline (10 ug/ml) for growth overnight on a 37C rotator. 100 ul of each overnight culture 4 was then inoculated into 10 ml of LB containing carbenicillin (50 ug/ml) and tetracycline (10 ug/ml) and IPTG 5 (5mM) and incubated on a 37C rotator for 4 hours. Each bacterial growth was then centrifuged at 3500 X G for 6 25 minutes, decanted, and the pellet resuspended in 0.5 ml of LB containing carbenicillin (50 ug/ml), tetracycline 7 (10 ug/ml), and IPTG (5 mM). To verify RNAi conditions' plasmid DNA, each RNAi clone was purified and 8 assessed through PCR (polymerase chain reaction) with sequence-specific primers or through Sanger 9 sequencing. 10 11
Nematode paralysis assays 12
Paralysis assays were performed by visually inspecting animals daily to determine if they were capable of 13 spontaneous movement or if they were paralyzed. A robotic system equipped with a digital camera was used 14 to obtain images of individual wells of a 12 well-plate at 5-minute intervals over the entire course of the 15 experiment. Each well contained 30-40 individual animals expressing Aβ. Through analysis of serial images 16 from each plate, the age at which each animal stopped moving could be easily determined. We applied this 17 system to the transgenic Aβ model line GMC101 to determine the time of paralysis onset for each individual 18
animal. Paralysis data was plotted using Oasis2. Statistical significance of mean paralysis time-points between 19
RNAi conditions was determined by a weighted log-rank 72,73 test. 20
Prior to loading on the experimental plates, animal populations were amplified on high-growth plates seeded 21 with NA22 bacteria. Worm populations were developmentally synchronized by hypochlorite treatment, and the 22 remaining eggs were deposited on unseeded plates overnight. Synchronized larval stage 1 animals were washed 23 off unseeded plates and moved onto standard C. elegans RNAi plates containing carbenicillin (50 mg/ml), 24 tetracycline (10 mg/ml), and IPTG (5 mM) 48h at 20C. These developmentally synchronized, late larval stage 4-25 populations were then washed and transferred to their respective RNAi conditions on 12-well plates. We used 26 standard RNAi conditions plus FuDR (100 ug/ml) to prevent progeny and neomycin (200 mg/ml) to prevent 27 fungal growth. 74 Each RNAi condition was tested in 2-3 wells as technical replicates. At least three biological 28 replicates, each started on different weeks, were conducted for each RNAi clone. 29
30
Oxygen consumption assay 31
We quantified the oxygen consumption rates of day-two adult worms cultivated from L1 on Y53G8AL.2 RNAi 32 or the EV control RNAi at 20C. Oxygen consumption was measured utilizing the Seahorse X24 Bioanalyzer 33 (Seahorse Biosciences, MA, USA). 54 Briefly, young adult worms were washed from NGM plates and rinsed from 34
RNAi bacteria with M9 buffer. Approximately 40-50 worms were pipetted into each well in Seahorse XF24 Cell 35
Culture Microplates, with the final volume of 500µL M9. The number of worms in each well was 36 quantified. Basal respiration was analyzed using the average respiration of five technical replicates per condition, 37 and eight recordings over the course of an hour were made of each condition. Three independent biological 38 replicates were conducted on different weeks. For each experiment, we compared the relative rate of oxygen 39 consumption between the paired conditions. In each plate, nematode-free wells were used as control. Oxygen 40 consumption rates were then normalized by the number of worms. All three replicates showed that the animals 41 cultivated on the Y53G8AL.2 RNAi consumed about half as much oxygen as those grown on the control RNAi 42 bacteria (Figure 9 ). 43
Multi-omic module network learning 1
Given a matrix of values for each variable-sample pair from a number of variables and a number of samples, 2 MGL iteratively learns an assignment of the variables to a user-supplied number of modules and the conditional 3 dependence network among modules. In a conditional dependence module network, two modules that are 4 disconnected are independent of each other given all other modules. 5
For the MGL algorithm to run in a reasonable amount of time, from the 420,132 DNA methylation sites in the 6 ROSMAP data, we selected 20,132 DNA methylation sites with the highest variance across samples. 7
Supplementary Figure 3 shows the standard deviation of all methylation sites; the red vertical line represents 8 the standard deviation threshold we used to select the methylation sites to use in MGL. In addition to DNA 9 methylation levels, we used expression levels of 14,912 protein-coding genes and 309 miRNAs from the 10 ROSMAP study. Thus, we learned a network of modules from a total of 35,354 variables. We set the module 11 count to 500 before running the algorithm. 
